Pitching Early-Stage Science Under Uncertainty: A Milestone-Driven Governance Framework for Preclinical Ventures

Abstract

Early-stage life science ventures operate under conditions of extreme biological, regulatory, and economic uncertainty. They routinely struggle to communicate decision readiness to investors and industry partners because conventional pitch decks and business plans emphasize narrative ambition, market size, and long- term upside while under-specifying scientific risk, regulatory uncertainty, and staged decision logic. Research in translational medicine, venture governance, real options theory, and stage-gate innovation governance shows that investors and organizations allocate early-stage capital to resolve dominant uncertainties through incremental, sequential learning, tying continuation decisions to predefined technical and commercial criteria rather than to persuasive vision alone. Despite this logic, early-stage pitching practices rarely operationalize explicit continuation, narrowing/redesign, or termination thresholds within their artifact design.